Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Deep Learning for Distinguishing Morphological Features of Acute Promyelocytic Leukemia

John-William Sidhom, MSc, Ingharan J Siddarthan, Bo-Shiun Lai, PhD, Adam Luo, Bryan Hambley, MD, Jennifer Bynum, MD, Amy S. Duffield, MD PhD, Michael B. Streiff, MD, Alison R. Moliterno, MD, Philip H. Imus, MD, Christian B. Gocke, MD PhD, Lukasz P. Gondek, MDPhD, Amy E. DeZern, MD, Alexander S Baras, MDPhD, Thomas S. Kickler, MD, Mark Levis, MD PhD, Eugene Shenderov, MDDPhil

Blood (2020) 136 (Supplement 1): 10–12.

https://doi.org/10.1182/blood-2020-135836

Published: 2020

Journal Articles

The High Mobility Group A1 Chromatin Regulator Is Required for Pathologic Megakaryocyte Development and Progression to Myelofibrosis in JAK2V617F Murine Models

Alison R. Moliterno, MD, Donna Marie Williams, PhD, Liping Li, MD PhD, Lingling Xian, MD PhD, Li Luo, PhD, Amy S. Duffield, MD PhD, Ophelia Rogers, Jerry L. Spivak, MD, Linda Resar, MD

Blood (2019) 134 (Supplement_1): 472.

https://doi.org/10.1182/blood-2019-131432

Published: 2019

Journal Articles

DOCK2 Expression Affects Leukemogenesis and Disease Progression in a Murine Model of FLT3/ITD Acute Myeloid Leukemia

Min Wu, PhD, Li Li, MD PhD, Donald Small, MD PhD, Amy S. Duffield, MD PhD

Blood (2019) 134 (Supplement_1): 2534.

https://doi.org/10.1182/blood-2019-129157

Published: 2019

Journal Articles

Gilteritinib and Venetoclax Synergize to Eliminate FLT3/ITD+ Leukemia Cells through BIM

Ruiqi Zhu, PhD, Li Li, MD PhD, Bao Nguyen, MS, Amy S. Duffield, MD PhD, Donald Small, MD PhD

Blood (2019) 134 (Supplement_1): 2564.

https://doi.org/10.1182/blood-2019-131635

Published: 2019

Journal Articles

Mechanism of Escape from LNK Negative Regulation: Constitutively Active JAK2V617F Retains Lysine63-Ubiquitin

Jeffrey Patterson-Fortin, MD PhD, Jerry L. Spivak, MD, Amy S. Duffield, MD PhD, Donna Marie Williams, PhD, Ophelia Rogers, Zhizhuang Joe Zhao, PhD, Alison R. Moliterno, MD

Blood (2017) 130 (Supplement 1): 2931.

https://doi.org/10.1182/blood.V130.Suppl_1.2931.2931

Published: 2017

Journal Articles

Immunological Correlates of Treatment with the CTLA-4 Inhibitor Ipilimumab in Patients with Refractory Myelodysplastic Syndromes (MDS)

Blood (2017) 130 (Supplement 1): 1699.

https://doi.org/10.1182/blood.V130.Suppl_1.1699.1699

Published: 2017

Journal Articles

DOCK2 Knockdown Mitigates Disease Progression in Murine Models Harboring a FLT3/ITD Mutation

Min Wu, PhD, Li Li, MD PhD, Bao Nguyen, MS, Donald Small, MD PhD, Amy S. Duffield, MD PhD

Blood (2017) 130 (Supplement 1): 1216.

https://doi.org/10.1182/blood.V130.Suppl_1.1216.1216

Published: 2017

Journal Articles

Arsenic Trioxide Synergizes with FLT3 Tyrosine Kinase Inhibitors to Kill FLT3-ITD + Leukemic Cells through Depressed Production and Degradation of FLT3 Protein

Kozo Nagai, MD PhD, Lihong Hou, MD PhD, Li Li, MD PhD, Bao Nguyen, M.S., Courtney M Shirley, PhD, Hayley S Ma, PhD, Mark J. Levis, MD PhD, Amy S. Duffield, MD PhD, Donald Small, MD PhD

Blood (2016) 128 (22): 1568.

https://doi.org/10.1182/blood.V128.22.1568.1568

Published: 2016

Journal Articles

FLT3/ITD Cooperates with Rac1/DOCK2 to Modulate the Sensitivity of Leukemic Cells to Chemotherapeutic Agents Via Regulation of DNA Repair Pathways

Min Wu, PhD, Li Li, PhD, Max Hamaker, BA, Donald Small, MD PhD, Amy S. Duffield, MD PhD

Blood (2016) 128 (22): 2732.

https://doi.org/10.1182/blood.V128.22.2732.2732

Published: 2016

Journal Articles

A Wilms Tumor 1 (WT1) Mutation Causes Myelodysplastic Syndrome in a Knock-in Mouse Model, and a Mixed Myelodysplastic/Myeloproliferative Neoplam in Double Knock-in Mice with WT1 and FLT3/ITD Mutations

Colleen E. Annesley, MD, Amy S. Duffield, MD PhD, Rachel E. Rau, MD, Gregory McCarty, Daniel Magoon, Li Li, MD PhD, Vicki Huff, PhD, Donald Small, MD PhD, David Loeb, MD PhD, Patrick Brown, MD

Blood (2015) 126 (23): 312.

https://doi.org/10.1182/blood.V126.23.312.312

Published: 2015

Journal Articles

FLT3 Inhibition and Retinoid Signaling Overcome Stromal Protection to Target FLT3/ITD-Expressing Leukemia Stem Cells in the Bone Marrow Microenvironment

Hayley S Ma, PhD, Megan E McCray, BA, Courtney M Shirley, PhD, Amy S. Duffield, MD PhD, J Kyle Bruner, Li Li, PhD, Bao Nguyen, M.S., Sarah Greenblatt, PhD, Eric Jung, BS, Peter D. Aplan, MD, Richard J Jones, MD, Donald Small, MD PhD, Gabriel Ghiaur, MD PhD

Blood (2015) 126 (23): 790.

https://doi.org/10.1182/blood.V126.23.790.790

Published: 2015

Journal Articles

Lymphoproliferative Disease Risk in Patients with Autoimmune Disease: Clustering of Primary CNS Lymphoma with Drug Regimen and Disease Process

Genevieve Marie Crane, MD PhD, Helen Powell, PhD, Rumen Kostadinov, PhD, Peter C. Burger, MD, Richard F. Ambinder, MD PhD, Lode J. Swinnen, MBChB, Michael J. Borowitz, MD PhD, Amy S. Duffield, MD PhD

Blood (2015) 126 (23): 1490.

https://doi.org/10.1182/blood.V126.23.1490.1490

Published: 2015

Journal Articles

DOCK2 Regulates DNA Damage Response and Modulates the Sensitivity to Chemotherapeutic Agents in FLT3/ITD Leukemic Cells

Min Wu, PhD, Li Li, PhD, Max Hamaker, BA, Donald Small, MD PhD, Amy S. Duffield, MD PhD

Blood (2015) 126 (23): 3668.

https://doi.org/10.1182/blood.V126.23.3668.3668

Published: 2015

Journal Articles

MPL SV , a Unique MPN MPL Splice Variant, Provokes a Fulminant Myeloid Leukemia in a JAK2 V617F Transgenic Mouse Model of Polycythemia Vera

Jerry L. Spivak, MD, Donna Marie Williams, PhD, Zhizhuang Joe Zhao, PhD, Ophelia Rogers, Amy S. Duffield, MD PhD, W. David Hankins, PhD, Alison R Moliterno, MD

Blood (2015) 126 (23): 484.

https://doi.org/10.1182/blood.V126.23.484.484

Published: 2015

Journal Articles

Burkitt Leukemia Involving Only the Bone Marrow Has a Better Prognosis Than Widespread Burkitt Lymphoma Involving the Bone Marrow in Adults

Joo Y Song, MD, Girish Venkataraman, MD MBBS, Yuri D. Fedoriw, MD, Mir Alikhan, MD, Young Kim, MD, Dennis D. Weisenburger, MD, Joyce Collins, PhD, Xueli Liu, PhD, Amy S. Duffield, MD PhD

Blood (2014) 124 (21): 4446.

https://doi.org/10.1182/blood.V124.21.4446.4446

Published: 2014

Journal Articles

A Rise in CNS Lymphoproliferative Disease Incidence Reveals a Protective Role of Calcineurin Inhibitors

Genevieve M. Crane, MD PhD, Helen Powell, PhD, Rumen Kostadinov, PhD, Richard F. Ambinder, MD PhD, Lode J. Swinnen, Michael Borowitz, MD PhD, Amy S. Duffield, MD PhD

Blood (2014) 124 (21): 3020.

https://doi.org/10.1182/blood.V124.21.3020.3020

Published: 2014

Journal Articles

Late-Relapse Diffuse Large B-Cell Lymphoma Frequently Represents Recurrence of the Original Disease, and Demonstrates Evidence of Superimposed Clonal Heterogeneity and Clonal Evolution

Rena R. Xian, MD, Genevieve M. Crane, MD PhD, Lisa M. Haley, Christopher D. Gocke, MD, Ming-Tseh Lin, MD PhD, Aparna Pallavajjalla, Michael J. Borowitz, MD PhD, Lode J. Swinnen, Amy S. Duffield, MD PhD

Blood (2014) 124 (21): 2955.

https://doi.org/10.1182/blood.V124.21.2955.2955

Published: 2014

Journal Articles

DOCK2 Interacts with FLT3 and Modulates the Survival of FLT3-Expressing Leukemia Cells

Min Wu, PhD, Max Hamaker, BA, Li Li, PhD, Donald Small, MD PhD, Amy S. Duffield, MD PhD

Blood (2014) 124 (21): 3584.

https://doi.org/10.1182/blood.V124.21.3584.3584

Published: 2014

Journal Articles

Dnmt3a Deletion Cooperates with the Flt3-ITD Mutation to Drive Leukemogenesis in a Murine Model

Jennifer L Poitras, BS, Diane Heiser, PhD, Li Li, PhD, Bao Nguyen, M.S., Amy S. Duffield, MD PhD, Christopher Gamper, MD PhD, Donald Small, MD PhD

Blood (2014) 124 (21): 3568.

https://doi.org/10.1182/blood.V124.21.3568.3568

Published: 2014

Journal Articles

All- Trans Retinoic Acid Synergizes With FLT3 Tyrosine Kinase Inhibition To Eliminate FLT3/ITD-Expressing Leukemia Cells

Hayley S Ma, Ph.D., Sarah M Greenblatt, PhD, Eric Jung, B.S., Amy S. Duffield, MD, PhD, Li Li, PhD, Gabriel Ghiaur, MD, PhD, Richard J. Jones, Donald Small, MD, PhD

Blood (2013) 122 (21): 3960.

https://doi.org/10.1182/blood.V122.21.3960.3960

Published: 2013

NARROW

Deep Learning for Distinguishing Morphological Features of Acute Promyelocytic Leukemia

The High Mobility Group A1 Chromatin Regulator Is Required for Pathologic Megakaryocyte Development and Progression to Myelofibrosis in JAK2V617F Murine Models

DOCK2 Expression Affects Leukemogenesis and Disease Progression in a Murine Model of FLT3/ITD Acute Myeloid Leukemia

Gilteritinib and Venetoclax Synergize to Eliminate FLT3/ITD+ Leukemia Cells through BIM

Mechanism of Escape from LNK Negative Regulation: Constitutively Active JAK2V617F Retains Lysine63-Ubiquitin

Immunological Correlates of Treatment with the CTLA-4 Inhibitor Ipilimumab in Patients with Refractory Myelodysplastic Syndromes (MDS)

DOCK2 Knockdown Mitigates Disease Progression in Murine Models Harboring a FLT3/ITD Mutation

Arsenic Trioxide Synergizes with FLT3 Tyrosine Kinase Inhibitors to Kill FLT3-ITD + Leukemic Cells through Depressed Production and Degradation of FLT3 Protein

FLT3/ITD Cooperates with Rac1/DOCK2 to Modulate the Sensitivity of Leukemic Cells to Chemotherapeutic Agents Via Regulation of DNA Repair Pathways

A Wilms Tumor 1 (WT1) Mutation Causes Myelodysplastic Syndrome in a Knock-in Mouse Model, and a Mixed Myelodysplastic/Myeloproliferative Neoplam in Double Knock-in Mice with WT1 and FLT3/ITD Mutations

FLT3 Inhibition and Retinoid Signaling Overcome Stromal Protection to Target FLT3/ITD-Expressing Leukemia Stem Cells in the Bone Marrow Microenvironment

Lymphoproliferative Disease Risk in Patients with Autoimmune Disease: Clustering of Primary CNS Lymphoma with Drug Regimen and Disease Process

DOCK2 Regulates DNA Damage Response and Modulates the Sensitivity to Chemotherapeutic Agents in FLT3/ITD Leukemic Cells

MPL SV , a Unique MPN MPL Splice Variant, Provokes a Fulminant Myeloid Leukemia in a JAK2 V617F Transgenic Mouse Model of Polycythemia Vera

Burkitt Leukemia Involving Only the Bone Marrow Has a Better Prognosis Than Widespread Burkitt Lymphoma Involving the Bone Marrow in Adults

A Rise in CNS Lymphoproliferative Disease Incidence Reveals a Protective Role of Calcineurin Inhibitors

Late-Relapse Diffuse Large B-Cell Lymphoma Frequently Represents Recurrence of the Original Disease, and Demonstrates Evidence of Superimposed Clonal Heterogeneity and Clonal Evolution

DOCK2 Interacts with FLT3 and Modulates the Survival of FLT3-Expressing Leukemia Cells

Dnmt3a Deletion Cooperates with the Flt3-ITD Mutation to Drive Leukemogenesis in a Murine Model

All- Trans Retinoic Acid Synergizes With FLT3 Tyrosine Kinase Inhibition To Eliminate FLT3/ITD-Expressing Leukemia Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only